Moderna Omicron Booster: A clinical trial of a COVID-19 booster vaccine for volunteers ages 16 and older

A clinical trial conducted by Moderna is evaluating an investigational booster vaccine that may protect against the COVID-19 Omicron variant.

Trial ID: mRNA-1273-P305 [EudraCT ID: 2022-000063-51]

Estimated Enrolment

3,000 Participants

Trial Details

The mRNA-1273-P305 clinical trial is evaluating the safety and immune response of the investigational mRNA-1273.529 booster vaccine that may protect against the COVID-19 Omicron variant. The investigational mRNA-1273.529 booster is being compared to a booster dose of Moderna’s COVID-19 vaccine, Spikevax, which is the vaccine that received conditional marketing authorization in the EU. All participants will receive either mRNA-1273.529 or Spikevax.

With different strains of COVID-19, there is an urgent need to develop vaccination plans that will provide greater protection. A booster vaccine that protects against COVID-19 variants, including the Omicron variant, would be a crucial public health tool to help curb the pandemic.

Eligibility criteria

Participants must:

  • Be 16 years of age or older
  • Be in good health
  • Have previously received two or three doses of the COVID-19 vaccine
    • Participants who have previously received a third dose must have received an mRNA vaccine (Moderna, Pfizer/BioNTech) as a third dose
    • Participants who have previously received two doses may have received mRNA (Moderna, Pfizer/BioNTech) or non-mRNA (Oxford/AstraZeneca, Janssen) vaccines

If you are interested in taking part in this trial, please check your eligibility by completing our pre-screening questionnaire, found here: Citeline Connect (